BIAL strengthens its Board of Directors with Pierluigi Antonelli

BIAL, a century-old biopharmaceutical company focused on innovation, has announced the appointment of Pierluigi Antonelli, current member of the Board of Directors of Fresenius and President and CEO of Fresenius Kabi, as a non-executive member of its Board of Directors.

For Antonio Horta-Osorio, Chairman of BIAL, "Pierluigi Antonelli has built a remarkable career in the pharmaceutical and healthcare sector. We are delighted to have him on the Board of Directors of BIAL, and we are certain that we will benefit from his vast experience, further strengthening the Board's capabilities with his in-depth knowledge of the market.”

According to Pierluigi Antonelli, "After many years in leadership positions in some of the largest companies in the sector, it is clear to me the remarkable path that BIAL has achieved in its 100-year history. This company clearly represents resilience, strategy and research. It is with great satisfaction and a sense of challenge that I have agreed to join BIAL's Board of Directors, and I am excited to be able to contribute to the company's continued scientific advancement and bring innovative medicines to market."

Pierluigi Antonelli has a 25-year career in the pharmaceutical industry, with experience in the Biosciences, Organics and Generics sectors. In his previous role, he was CEO of Angelini Pharma, having held leadership roles in companies such as Novartis Oncology, Sandoz, Merck & Co and Bristol-Myers Squibb, both in the United States and Europe.

Pierluigi Antonelli holds an MBA from the Kellogg School of Management in the United States and a degree in Economics from the Libera Università Internazionale degli Studi Sociali in Italy.